Cannell & Co’s Fulcrum Therapeutics FULC Stock Holding History

Cannell & Co’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-22,400	Closed	-$410K	–	251
2020 Q2	$410K	Hold	22,400	–	–	0.02%	185
2020 Q1	$267K	Buy	+22,400	New	+$358K	0.01%	201

Other funds holding FULC

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Cannell & Co's FULC Position: Q3 2020 in Review

Cannell & Co sold out of Fulcrum Therapeutics (FULC) in Q3 2020, closing a stake of 22,400 shares — an estimated $410K sold.

Cannell & Co first reported a position in FULC in Q1 2020 and held it in 2 quarters. The position peaked at $410K in Q2 2020. 55 funds tracked by Wall St. Rank hold FULC as of Q3 2020.

Cannell & Co reported no remaining Fulcrum Therapeutics position as of Q3 2020 after selling out during the quarter.
Cannell & Co sold 22,400 Fulcrum Therapeutics shares in Q3 2020, an estimated $410K.
Cannell & Co first reported a position in Fulcrum Therapeutics in Q1 2020 and held it in 2 quarters.
Cannell & Co's Fulcrum Therapeutics position peaked at $410K in Q2 2020.
55 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q3 2020.

Based on Cannell & Co's 13F filing for Q3 2020, filed 12 Nov 2020.